Next Biotech

Learn More about Next Investors - Experts in Biotech Stocks

Autism Trial Results a Major Boost for NTI’s Proprietary Tech & Children with Autism

Next Investors Archived Jul 10, 2018

Leading medical device company Neurotech International (ASX:NTI) this week reported highly promising results from US clinical trials of its Mente autism device.

Revolutionary MedTech Device: a New Frontier in Autism Treatment

Next Investors Archived Jun 26, 2018

Today’s company has created the first and only regulated medical device for the management of autism in a home setting.

IMC Reports Rising Revenues & Eyes Colitis Market

Next Investors Archived Jun 07, 2018

Immuron Limited (ASX:IMC | NASDAQ:IMRN) is focused on developing and commercialising orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases.

Top Results: BD1 Continues to Boost its Ovarian Cancer Detection Studies

Next Investors Archived May 21, 2018

BARD1 Life Sciences Limited (ASX:BD1) has both lung and ovarian cancer in its sights.

PTX Breast Cancer Trial Results Exceed Industry Expectations

Next Investors Archived May 17, 2018

Prescient Therapeutics (ASX:PTX) is looking to prove up its two breast cancer therapies, putting it ahead of the field in areas of high unmet need.

CPH Continues to Expand Global Footprint As it Moves Into Israeli Cannabis Market

Next Investors Archived May 16, 2018

Creso Pharma (ASX:CPH) has today informed the market that it has entered into a joint venture with Cohen Propagation Nurseries Limited to operate a high quality medicinal cannabis growing facility in Israel.

MXC to Build Malta Production Facility to Capitalise on $55B Global Pot Market

Next Investors Archived Apr 12, 2018

MGC Pharmaceuticals (ASX:MXC) has wasted no time ramping up its game in 2018.

ASX Junior at the Forefront of Cancer Research Could be Set for a Blockbuster Year

Next Investors Archived Mar 13, 2018

This biotech appears to have cracked one of the holy grails of cancer research: it’s currently in human clinical trials with not one, but two innovative drugs which ‘turn off the switch’ that would otherwise allow cancerous cells to grow via the important Akt and Ras pathways.

Blockbuster Results from IMC’s NASH Liver Therapy Trials

Next Investors Archived Mar 08, 2018

Australian microbiome biopharmaceutical company, Immuron Limited (ASX:IMC | NASDAQ:IMRN) continues to progress its oral immunotherapies, to supply solutions for a growing unmet need.

RSH on verge of commercialisation: on track to complete next-generation AirSonea

Next Investors Archived Feb 23, 2018

Respiri (ASX:RSH) is leading the way in new technologies to better manage asthma, a chronic disease affecting more than 330 million worldwide.

CPH Gets Green Light to Distribute its Innovative CBD Based Nutraceutical Products in the UK

Next Investors Archived Jan 18, 2018

While much of the business world shut down over the Christmas-New Year’s break, diversified cannabis healthcare company Creso Pharma (ASX:CPH) has been busy on a number of fronts.

CPH Seal Swiss Pharma Deal: Setting the Cornerstone for Global Commercialisation of cannaQIX

Next Investors Archived Dec 04, 2017

It has been a major month for Creso Pharma (ASX:CPH) as it continues to make potentially market moving announcements.

Budding ASX Junior Pens Transformative Medical Cannabis Deals: Now Generating Revenue

Next Investors Archived Nov 23, 2017

MGC Pharmaceuticals (ASX:MXC) was the second company to originally emerge in the ASX cannabis corridor, and with a whip-smart team that’s put in serious hours in the industry-leading Israeli medicinal marijuana scene, this ASX junior is rapidly coming into its own.

Could One ASX Junior Have All the Elements to Crack $121BN Natural Skincare Market?

Next Investors Archived Nov 15, 2017

This Australian-based developer of US FDA and Australia TGA approved natural and organic skin care products already has mainstream reach spanning over 15 countries, through its 100% natural and organic sunscreen Soleo Organics and is set to launch its organics sunscreen range into the US$10BN global suncare market.

CPH Launches First Animal Product in Partnership with Global Animal Health Giant

Next Investors Archived Nov 14, 2017

Creso Pharma (ASX: CPH) has hit a major milestone with the launch of its first animal health product in Switzerland and Lichtenstein.

IMU Picks up the Pace in Cancer Drug Treatment Development

Next Investors Archived Aug 09, 2017

It is difficult to understate the possible impact of the immuno-oncology therapies that the $33 million-capped Imugene (ASX: IMU) is currently developing. These therapies, if proven safe and successful, could have an undeniable real world positive effect for cancer patients.

CPH to Acquire Canadian Cannabis Grower and Strengthen Position in Multi-Billion Dollar Market

Next Investors Archived Jul 27, 2017

Creso Pharma (ASX:CPH) is now in the box seat to acquire 100% of Canadian-based Mernova Medicinal Inc., an acquisition that would position CPH as a Canadian producer of legal cannabis.

CPH Signs Exclusive Cannapharm deal: On Track for 2017 Product Release

Next Investors Archived Jun 14, 2017

News of $100 million IPOs, alongside an avalanche of parallel legislative changes around the world, builds a strong case for the burgeoning medicinal marijuana industry. With so many medicinal cannabis stocks fighting for market share and threatening to steal the limelight, a company such as Creso Pharma Ltd (ASX: CPH) needs to do all it can to stay current and competitive.

< prev Page 4 of 7 next >